Click here to get full coverage on $CATX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

$CATX stock is down 17% today. Here's what we see in our data.  Quiver Quantitative

$CATX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Momentum Shift: Will CATX benefit from rising consumer demand - Quarterly Market Summary & High Win Rate Trade Tips - baoquankhu1.vn

Momentum Shift: Will CATX benefit from rising consumer demand - Quarterly Market Summary & High Win Rate Trade Tips  baoquankhu1.vn

Momentum Shift: Will CATX benefit from rising consumer demand - Quarterly Market Summary & High Win Rate Trade Tips - baoquankhu1.vn

Click here to get full coverage on Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 0.4% - Should You Buy? - MarketBeat

Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 0.4% - Should You Buy?  MarketBeat

Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 0.4% - Should You Buy? - MarketBeat

Click here to get full coverage on CATX: Radiopharmaceuticals deliver high response rates and safety in solid tumors, driving oncology innovation - TradingView — Track All Markets

CATX: Radiopharmaceuticals deliver high response rates and safety in solid tumors, driving oncology innovation  TradingView — Track All Markets

CATX: Radiopharmaceuticals deliver high response rates and safety in solid tumors, driving oncology innovation - TradingView — Track All Markets

Click here to get full coverage on Could CATX’s New ESMO Data Reveal a Shift in Its Long-Term Oncology Innovation Strategy? - Yahoo Finance

Could CATX’s New ESMO Data Reveal a Shift in Its Long-Term Oncology Innovation Strategy?  Yahoo Finance

Could CATX’s New ESMO Data Reveal a Shift in Its Long-Term Oncology Innovation Strategy? - Yahoo Finance

Click here to get full coverage on Williamson buys Perspective Therapeutics (CATX) shares worth $19,945 - Investing.com

Williamson buys Perspective Therapeutics (CATX) shares worth $19,945  Investing.com

Williamson buys Perspective Therapeutics (CATX) shares worth $19,945 - Investing.com

Click here to get full coverage on BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News - GuruFocus

BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News  GuruFocus

BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News - GuruFocus

Click here to get full coverage on Perspective Therapeutics (CATX): Assessing Valuation After ESMO Data Release and Sharp Share Price Drop - simplywall.st

Perspective Therapeutics (CATX): Assessing Valuation After ESMO Data Release and Sharp Share Price Drop  simplywall.st

Perspective Therapeutics (CATX): Assessing Valuation After ESMO Data Release and Sharp Share Price Drop - simplywall.st

Click here to get full coverage on BTIG Reiterates Perspective Therapeutics (CATX) Buy Recommendation - Nasdaq

BTIG Reiterates Perspective Therapeutics (CATX) Buy Recommendation  Nasdaq

BTIG Reiterates Perspective Therapeutics (CATX) Buy Recommendation - Nasdaq

Click here to get full coverage on CatX and Cactus to merge, launch AI-driven risk platform in Bermuda - Reinsurance News

CatX and Cactus to merge, launch AI-driven risk platform in Bermuda  Reinsurance News

CatX and Cactus to merge, launch AI-driven risk platform in Bermuda - Reinsurance News

Click here to get full coverage on CatX to merge with Cactus, double-down on AI powered risk decisions and exchange - Artemis.bm

CatX to merge with Cactus, double-down on AI powered risk decisions and exchange  Artemis.bm

CatX to merge with Cactus, double-down on AI powered risk decisions and exchange - Artemis.bm

Click here to get full coverage on Experimental targeted radiation shows tumor shrinkage in early trial - Stock Titan

Experimental targeted radiation shows tumor shrinkage in early trial  Stock Titan

Experimental targeted radiation shows tumor shrinkage in early trial - Stock Titan

Click here to get full coverage on CATX: Strong clinical results, scalable manufacturing, and robust pipeline drive growth prospects - TradingView — Track All Markets

CATX: Strong clinical results, scalable manufacturing, and robust pipeline drive growth prospects  TradingView — Track All Markets

CATX: Strong clinical results, scalable manufacturing, and robust pipeline drive growth prospects - TradingView — Track All Markets

Click here to get full coverage on Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research - MarketBeat

Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research  MarketBeat

Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research - MarketBeat

Click here to get full coverage on New Analyst Forecast: $CATX Given $7.0 Price Target | CATX Stock News - Quiver Quantitative

New Analyst Forecast: $CATX Given $7.0 Price Target | CATX Stock News  Quiver Quantitative

New Analyst Forecast: $CATX Given $7.0 Price Target | CATX Stock News - Quiver Quantitative

Click here to get full coverage on New Analyst Forecast: $CATX Given 'Buy' Rating | CATX Stock News - Quiver Quantitative

New Analyst Forecast: $CATX Given 'Buy' Rating | CATX Stock News  Quiver Quantitative

New Analyst Forecast: $CATX Given 'Buy' Rating | CATX Stock News - Quiver Quantitative

Click here to get full coverage on New Analyst Forecast: $CATX Given $10.0 Price Target | CATX Stock News - Quiver Quantitative

New Analyst Forecast: $CATX Given $10.0 Price Target | CATX Stock News  Quiver Quantitative

New Analyst Forecast: $CATX Given $10.0 Price Target | CATX Stock News - Quiver Quantitative

Click here to get full coverage on BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $4 - 富途资讯

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $4  富途资讯

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $4 - 富途资讯

Click here to get full coverage on Perspective (NYSE American: CATX) to report Q3 results and business update Nov. 10 - Stock Titan

Perspective (NYSE American: CATX) to report Q3 results and business update Nov. 10  Stock Titan

Perspective (NYSE American: CATX) to report Q3 results and business update Nov. 10 - Stock Titan

Click here to get full coverage on Do Investors Expect Too Much From CATX as [212Pb]VMT-α-NET Shows Promising but Mixed Results? - simplywall.st

Do Investors Expect Too Much From CATX as [212Pb]VMT-α-NET Shows Promising but Mixed Results?  simplywall.st

Do Investors Expect Too Much From CATX as [212Pb]VMT-α-NET Shows Promising but Mixed Results? - simplywall.st

Click here to get full coverage on Perspective (NYSE American: CATX) reports 80% progression-free in VMT-α-NET, no DLTs - Stock Titan

Perspective (NYSE American: CATX) reports 80% progression-free in VMT-α-NET, no DLTs  Stock Titan

Perspective (NYSE American: CATX) reports 80% progression-free in VMT-α-NET, no DLTs - Stock Titan

Click here to get full coverage on Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference  Yahoo Finance

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance

Click here to get full coverage on Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential - Yahoo Finance

Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential  Yahoo Finance

Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential - Yahoo Finance

Click here to get full coverage on JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18 - 富途资讯

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18  富途资讯

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18 - 富途资讯

Click here to get full coverage on Perspective Therapeutics Reports 44% ORR in Cohort 2 | CATX Stock News - Stock Titan

Perspective Therapeutics Reports 44% ORR in Cohort 2 | CATX Stock News  Stock Titan

Perspective Therapeutics Reports 44% ORR in Cohort 2 | CATX Stock News - Stock Titan

Click here to get full coverage on CatX CEO explains unique offering, fresh from Cactus merger - Intelligent Insurer

CatX CEO explains unique offering, fresh from Cactus merger  Intelligent Insurer

CatX CEO explains unique offering, fresh from Cactus merger - Intelligent Insurer

Click here to get full coverage on Perspective Therapeutics (CATX) Shares Plunge on Clinical Trial Results - GuruFocus

Perspective Therapeutics (CATX) Shares Plunge on Clinical Trial Results  GuruFocus

Perspective Therapeutics (CATX) Shares Plunge on Clinical Trial Results - GuruFocus

Click here to get full coverage on Catex - ICO Drops

Catex - ICO Drops

Click here to get full coverage on Perspective Therapeutics to Engage with Investors at Upcoming Conferences | CATX Stock News - Quiver Quantitative

Perspective Therapeutics to Engage with Investors at Upcoming Conferences | CATX Stock News  Quiver Quantitative

Perspective Therapeutics to Engage with Investors at Upcoming Conferences | CATX Stock News - Quiver Quantitative

Click here to get full coverage on Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference  GlobeNewswire

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Click here to get full coverage on CatX and Cactus merge to form Bermuda’s biggest insurance software firm - Beinsure

CatX and Cactus merge to form Bermuda’s biggest insurance software firm  Beinsure

CatX and Cactus merge to form Bermuda’s biggest insurance software firm - Beinsure

Click here to get full coverage on CatX and Cactus merger unveiled at Rendez-Vous - The Royal Gazette

CatX and Cactus merger unveiled at Rendez-Vous  The Royal Gazette

CatX and Cactus merger unveiled at Rendez-Vous - The Royal Gazette

Click here to get full coverage on Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals - TradingView — Track All Markets

Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals  TradingView — Track All Markets

Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals - TradingView — Track All Markets

Click here to get full coverage on Oppenheimer lowers Perspective Therapeutics stock price target on competitive data - Investing.com

Oppenheimer lowers Perspective Therapeutics stock price target on competitive data  Investing.com

Oppenheimer lowers Perspective Therapeutics stock price target on competitive data - Investing.com

Click here to get full coverage on Hunt Jonathan Robert buys Perspective Therapeutics shares - Investing.com

Hunt Jonathan Robert buys Perspective Therapeutics shares  Investing.com

Hunt Jonathan Robert buys Perspective Therapeutics shares - Investing.com

Click here to get full coverage on Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Nasdaq

Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround  Nasdaq

Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Nasdaq

Click here to get full coverage on Perspective Therapeutics Provides Business Updates and Strategic Priorities - TradingView — Track All Markets

Perspective Therapeutics Provides Business Updates and Strategic Priorities  TradingView — Track All Markets

Perspective Therapeutics Provides Business Updates and Strategic Priorities - TradingView — Track All Markets

Click here to get full coverage on BTIG initiates coverage on Perspective Therapeutics stock with Buy rating - Investing.com

BTIG initiates coverage on Perspective Therapeutics stock with Buy rating  Investing.com

BTIG initiates coverage on Perspective Therapeutics stock with Buy rating - Investing.com

Click here to get full coverage on Is Now The Time To Invest In Perspective Therapeutics (NYSE:CATX) - Seeking Alpha

Is Now The Time To Invest In Perspective Therapeutics (NYSE:CATX)  Seeking Alpha

Is Now The Time To Invest In Perspective Therapeutics (NYSE:CATX) - Seeking Alpha

Click here to get full coverage on Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline - TipRanks

Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline  TipRanks

Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline - TipRanks

Click here to get full coverage on Insider Buying: Jonathan Hunt Acquires 11,000 Shares of Perspective Therapeutics Inc (CATX) - GuruFocus

Insider Buying: Jonathan Hunt Acquires 11,000 Shares of Perspective Therapeutics Inc (CATX)  GuruFocus

Insider Buying: Jonathan Hunt Acquires 11,000 Shares of Perspective Therapeutics Inc (CATX) - GuruFocus

Click here to get full coverage on Perspective Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com

Perspective Therapeutics earnings missed by $0.03, revenue topped estimates  Investing.com

Perspective Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com

Click here to get full coverage on Oppenheimer lowers Perspective Therapeutics stock price target to $14 - Investing.com

Oppenheimer lowers Perspective Therapeutics stock price target to $14  Investing.com

Oppenheimer lowers Perspective Therapeutics stock price target to $14 - Investing.com

Click here to get full coverage on Why CATX stock is a strong analyst pick - Treasury Yields & Advanced Swing Trade Entry Plans - ulpravda.ru

Why CATX stock is a strong analyst pick - Treasury Yields & Advanced Swing Trade Entry Plans  ulpravda.ru

Why CATX stock is a strong analyst pick - Treasury Yields & Advanced Swing Trade Entry Plans - ulpravda.ru

Click here to get full coverage on CatX unveils AI-powered platform to streamline parametrics for investors - Artemis.bm

CatX unveils AI-powered platform to streamline parametrics for investors  Artemis.bm

CatX unveils AI-powered platform to streamline parametrics for investors - Artemis.bm

Click here to get full coverage on Perspective Therapeutics outlines 2026 clinical and manufacturing priorities - TipRanks

Perspective Therapeutics outlines 2026 clinical and manufacturing priorities  TipRanks

Perspective Therapeutics outlines 2026 clinical and manufacturing priorities - TipRanks

Click here to get full coverage on CatX partners with Cactus to enhance risk analytics, execution - Bermuda Re

CatX partners with Cactus to enhance risk analytics, execution  Bermuda Re

CatX partners with Cactus to enhance risk analytics, execution - Bermuda Re

Click here to get full coverage on Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data - TipRanks

Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data  TipRanks

Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data - TipRanks

Click here to get full coverage on RBC Capital raises Perspective Therapeutics stock price target to $16 - Investing.com

RBC Capital raises Perspective Therapeutics stock price target to $16  Investing.com

RBC Capital raises Perspective Therapeutics stock price target to $16 - Investing.com

Click here to get full coverage on Perspective Therapeutics Shows Promising Trial Results at ESMO - TipRanks

Perspective Therapeutics Shows Promising Trial Results at ESMO  TipRanks

Perspective Therapeutics Shows Promising Trial Results at ESMO - TipRanks

Click here to get full coverage on Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy  Seeking Alpha

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha

Click here to get full coverage on Best Stocks Under $5: Top Picks for 2026 - Intellectia AI

Best Stocks Under $5: Top Picks for 2026  Intellectia AI

Best Stocks Under $5: Top Picks for 2026 - Intellectia AI

Click here to get full coverage on Perspective Therapeutics Updates Executive Employment Agreements - TipRanks

Perspective Therapeutics Updates Executive Employment Agreements  TipRanks

Perspective Therapeutics Updates Executive Employment Agreements - TipRanks

Click here to get full coverage on Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results - GlobeNewswire

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results  GlobeNewswire

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results - GlobeNewswire

Click here to get full coverage on UBS lowers Perspective Therapeutics stock price target on competition concerns - Investing.com

UBS lowers Perspective Therapeutics stock price target on competition concerns  Investing.com

UBS lowers Perspective Therapeutics stock price target on competition concerns - Investing.com

Click here to get full coverage on Joel Sendek Replaces Juan Graham As Perspective Therapeutics' New CFO - Nasdaq

Joel Sendek Replaces Juan Graham As Perspective Therapeutics' New CFO  Nasdaq

Joel Sendek Replaces Juan Graham As Perspective Therapeutics' New CFO - Nasdaq

Click here to get full coverage on Scotiabank Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $15 - 富途资讯

Scotiabank Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $15  富途资讯

Scotiabank Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $15 - 富途资讯

Click here to get full coverage on A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $11 to $15 - 富途资讯

A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $11 to $15  富途资讯

A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $11 to $15 - 富途资讯

Click here to get full coverage on Precision Oncology Pioneer Perspective Therapeutics Takes Center Stage at Oppenheimer and B. Riley Conferences - Stock Titan

Precision Oncology Pioneer Perspective Therapeutics Takes Center Stage at Oppenheimer and B. Riley Conferences  Stock Titan

Precision Oncology Pioneer Perspective Therapeutics Takes Center Stage at Oppenheimer and B. Riley Conferences - Stock Titan

Click here to get full coverage on CatX launches AI-powered parametric platform - Reinsurance News

CatX launches AI-powered parametric platform  Reinsurance News

CatX launches AI-powered parametric platform - Reinsurance News

Click here to get full coverage on Is CATX stock a contrarian buy - July 2025 Intraday Action & Technical Pattern Alert System - bolumsonucanavari.com

Is CATX stock a contrarian buy - July 2025 Intraday Action & Technical Pattern Alert System  bolumsonucanavari.com

Is CATX stock a contrarian buy - July 2025 Intraday Action & Technical Pattern Alert System - bolumsonucanavari.com

Click here to get full coverage on Oppenheimer maintains CATX stock Outperform with $16 target By Investing.com - Investing.com UK

Oppenheimer maintains CATX stock Outperform with $16 target By Investing.com  Investing.com UK

Oppenheimer maintains CATX stock Outperform with $16 target By Investing.com - Investing.com UK

Click here to get full coverage on Best Crypto To Buy Now As BRM, CATX & AUTO Hit Top Gainers List - Outlook India

Best Crypto To Buy Now As BRM, CATX & AUTO Hit Top Gainers List  Outlook India

Best Crypto To Buy Now As BRM, CATX & AUTO Hit Top Gainers List - Outlook India

Click here to get full coverage on Perspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdles - Investing.com

Perspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdles  Investing.com

Perspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdles - Investing.com

Click here to get full coverage on CatX integrates Verisk catastrophe model capabilities into risk capital platform - Artemis.bm

CatX integrates Verisk catastrophe model capabilities into risk capital platform  Artemis.bm

CatX integrates Verisk catastrophe model capabilities into risk capital platform - Artemis.bm

Click here to get full coverage on Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance

Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025?  Yahoo Finance

Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance

Click here to get full coverage on CatX launches AI-powered parametric platform - The Royal Gazette

CatX launches AI-powered parametric platform  The Royal Gazette

CatX launches AI-powered parametric platform - The Royal Gazette

Click here to get full coverage on CatX launches Catamaran AI, provides feedback on investor interest & pricing - Artemis.bm

CatX launches Catamaran AI, provides feedback on investor interest & pricing  Artemis.bm

CATX

Price Chart

Key Statistics

Technicals

About CATX

Latest News

$CATX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

Momentum Shift: Will CATX benefit from rising consumer demand - Quarterly Market Summary & High Win Rate Trade Tips - baoquankhu1.vn

Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 0.4% - Should You Buy? - MarketBeat

Advanced Charts

Top Gainers

Top Losers